NVP-DKY709   Click here for help

GtoPdb Ligand ID: 12583

Synonyms: compound 5 [PMID: 36863346] | DKY-709 | DKY709
PDB Ligand
Compound class: Synthetic organic
Comment: NVP-DKY709 is a molecular glue type degrader, that promotes selective cereblon-mediated degradation of the IKZF2 ('Helios') transcription factor (IKZF2; Q9UKS7) [1]. It has no effect on IKZF1 (Ikaros) or IKZF3 (Aiolos). NVP-DKY709 is intended as a cancer immunotherapy agent that reduces regulatory T cell suppression, with the aim of re-establishing an anti-tumour immune response in the tumour microenvironment.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 69.72
Molecular weight 417.5
XLogP 0.8
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC=C(C=C1)CN2CCC(CC2)C3=CC=C4C(=C3)CN(C5CCC(=O)NC5=O)C4=O
Isomeric SMILES C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC(=C3)C4CCN(CC4)CC5=CC=CC=C5
InChI InChI=1S/C25H27N3O3/c29-23-9-8-22(24(30)26-23)28-16-20-14-19(6-7-21(20)25(28)31)18-10-12-27(13-11-18)15-17-4-2-1-3-5-17/h1-7,14,18,22H,8-13,15-16H2,(H,26,29,30)
InChI Key OMISHRJQMYQPMG-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
NVP-DKY709 has entered clinical evaluation for solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03891953 Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. Phase 1 Interventional Novartis